cro.directory
← Compare landing

Aragen Life Sciences vs PozeSCAF Inc.

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/aragen/pozescaf-discovery-solutions

CategoryAragen Life SciencesPozeSCAF Inc.
Listed sitecrocro
SummaryGlobal CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.Preclinical drug discovery CRO combining proprietary generative AI platform AxDrug with computational chemistry, synthetic chemistry, and in vitro biology to accelerate hit discovery and lead optimization for biotech and pharma clients.
Services
  • Discovery Research
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Computational & In-Silico Drug Discovery
  • Protein Engineering
  • In Vitro Pharmacology
  • In Vitro ADME / DMPK
  • Safety Pharmacology
  • Genetic Toxicology
  • Preclinical In Vitro Studies
  • Preclinical In Vivo Studies
  • In Vivo Efficacy Models
  • In Vivo PK / PD Studies
  • GLP Toxicology
  • Carcinogenicity Studies
  • DART (Reproductive & Developmental Toxicology)
  • Specialized & Large-Animal Models
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Immunogenicity Assays (ADA / NAb)
  • Biomarker Assays
  • Flow Cytometry Services
  • Analytical Method Development & Validation
  • ICH Stability Studies
  • Translational Research
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Regulatory Affairs
  • Computational & In-Silico Drug Discovery
  • Target Identification & Validation
  • High-Throughput Screening
  • Medicinal Chemistry
  • Discovery Research
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Antibody-Drug Conjugate (ADC)
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • Peptide
  • Vaccine
  • Small Molecule
  • Peptide
  • Antibody-Drug Conjugate (ADC)
Indications
  • Oncology
  • Immunology
  • Neurology
  • Psychiatry
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Respiratory
  • Dermatology
  • Ophthalmology
  • Gastroenterology
  • Nephrology
  • Women's Health
Data not yet provided.
Locations
  • Global Headquarters, Hyderabad, Telangana, India
  • R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Hyderabad, Telangana, India
  • Manufacturing Campus, Visakhapatnam, Andhra Pradesh, India
  • R&D Campus, Bengaluru, Karnataka, India
  • Biosafety Solutions, Pune, Maharashtra, India
  • Regional Office, New Delhi, Delhi, India
  • Sales Office, Tokyo, Japan
  • Sales Office, Seoul, South Korea
  • Sales Office, Cambridge, Massachusetts, USA
  • R&D Campus, Morgan Hill, California, USA
  • Sales Office, Utrecht, Netherlands
  • Sales Office, Milan, Italy
  • Sales Office, South Korea
  • Global Headquarters & R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Pune, Maharashtra, India
  • R&D Campus, New Delhi, Delhi, India
  • Sales Office, New Jersey, New Jersey, USA
  • Global Headquarters, R&D and Manufacturing Campus, Hyderabad, Telangana, India
  • R&D Campus, Mallapur, Hyderabad, India
Data not yet provided.
Certifications
  • USFDA · Identifier: EIR for Nacharam Unit 1
Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.